Introduction {#Sec1}
============

Breast cancer is the most common invasive cancer in women, accounting for roughly 232,000 new cases and 40,000 deaths annually, or approximately 15 % of cancer-related deaths in women in the United States \[[@CR1]\]. In Japan, the incidence of breast cancer increased from roughly 11,000 to 31,000 cases between 1975 and 1995, and is expected to increase to 50,000 cases by 2015 \[[@CR2]\].

Most breast cancers (60 %) express estrogen receptor (ER) or progesterone receptor (PgR) and are responsive to estrogens for growth and proliferation \[[@CR3]\]. Therefore, hormone-receptor-positive breast cancer can be treated by either blocking the ER with agents such as the selective ER modulator (SERM) tamoxifen, or by reducing the production of estrogens with aromatase inhibitors (AIs) \[[@CR4]--[@CR6]\].

Exemestane, a steroidal, irreversible AI structurally related to androstenedione, and anastrozole, a triazolic non-steroidal AI, are both approved in Japan for treatment of breast cancer in postmenopausal women. Results of studies directly comparing the efficacy and safety of AIs to tamoxifen or megestrol acetate for treatment of hormone-receptor-positive breast cancer in postmenopausal women have been extensively reported and indicate an overall favorable efficacy and safety profile for AIs compared with other agents \[[@CR7]--[@CR18]\]; however, only a limited number of studies have directly compared the efficacy and safety of different AIs (studies MA.27 \[[@CR19], [@CR20]\] and ACOSOG Z1031 \[[@CR21]\]), and these were conducted in patients with early breast cancer. The current study was a multicenter, randomized, double-blind, non-inferiority study conducted in Japan to evaluate time to progression (TTP) in postmenopausal patients with hormone-receptor-positive advanced and/or recurrent breast cancer randomized to treatment with either exemestane or anastrozole. This is the first large-scale direct comparison of the safety and efficacy of different AIs for first-line treatment of patients with advanced breast cancer.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

All patients provided written informed consent before participating in the trial. Postmenopausal patients at least 20 years of age with metastatic, progressive, or locally recurrent, inoperable, hormone-receptor-positive breast cancer confirmed histologically or cytologically at the time of primary tumor diagnosis or detection of metastasis were eligible. Enrollment ER and PgR status was determined at each participating site. When available, tumor tissues were further analyzed for some biomarkers as described below. Postmenopausal status was defined as no menstruation for 12 months before enrollment and follicle-stimulating hormone levels in the postmenopausal range. Patients who had 12 or more months of menopause induced by chemotherapy or luteinizing hormone-releasing hormone (LHRH) agonist and who were at least 45 years of age were also eligible. Additional eligibility requirements included Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or measureable bone lesions per Japanese Classification of Breast Cancer, Edition 14 \[[@CR22], [@CR23]\]. Patients who developed advanced or recurrent breast cancer during postoperative adjuvant hormonal therapy with anti-estrogen agents (e.g., tamoxifen) were also eligible; however, patients who received previous hormonal therapy (tamoxifen, LHRH agonists, ovariectomy), chemotherapy, or AI therapy for advanced breast cancer were not eligible. Patients with rapidly progressing disease, large-volume visceral disease, and brain metastases were also ineligible.

This study was conducted in compliance with the Declaration of Helsinki and its amendments and relevant International Conference on Harmonisation of Good Clinical Practice guidelines, and in agreement with the institutional boards.

Study design and treatment {#Sec4}
--------------------------

This was a multicenter, randomized, double-blind, phase 3 study conducted at 64 sites. Eligible patients received 2 tablets of the study drugs (exemestane 25 mg plus anastrozole placebo or anastrozole 1 mg plus exemestane placebo) and were instructed to take the tablets orally once daily with food. Treatment began within 14 days of receiving informed consent and continued until disease progression, intolerable adverse event (AE), or death.

Patients were randomized to balance for major prognostic factors including site of disease, postoperative adjuvant tamoxifen therapy, bisphosphonate use (pamidronate and/or zoledronic acid), and study site. The database was to be locked and the study unblinded after 228 events (disease progression or breast cancer death) had occurred as assessed by the expert radiologic images review committee (ERIRC).

Endpoints and assessments {#Sec5}
-------------------------

The primary endpoint was TTP, defined as the time from randomization to confirmed progressive disease or breast cancer death based on the ERIRC assessment. Patients last documented to be either alive, still on treatment or within 28 days of treatment discontinuation, or progression-free were censored at the date of the last objective disease assessment verifying lack of disease progression.

Secondary endpoints (based on RECIST version 1.0 criteria) included investigator-assessed TTP, overall survival (OS), objective response rate, clinical benefit rate, and time to treatment failure. Overall survival was defined as the time from the date of randomization to the date of death from any cause; patients last known to be alive were censored at the date of last contact. Time to treatment failure was defined as the time from the date of randomization to the date of first documentation of disease progression, symptomatic deterioration, death from any cause, or discontinuation of treatment due to AE, refusal, or other reason. Patients last known not to have failed treatment were censored at the date of the last visit that verified lack of treatment failure.

For patients with measurable disease, investigator- and ERIRC-assessed antitumor responses were assessed using RECIST version 1.0. For patients with measureable bone lesions, the Japanese Classification of Breast Cancer was used for assessments. Patients were assessed every 8 weeks up to week 48, every 12 weeks thereafter, and at the end of treatment or study withdrawal. Clinical benefit rate was defined as the proportion of patients who achieved complete response, partial response, or stable disease lasting at least 24 weeks.

The incidence and severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and the Japanese translated version of Japan Clinical Oncology Group (JCOG) criteria for AEs.

Exploratory assessments included the effect of tumor growth-related factors present at the time of diagnosis of advanced/recurrent breast cancer on the efficacy of exemestane or anastrozole treatment.

Immunohistochemical assays of biomarkers {#Sec6}
----------------------------------------

Immunohistochemical staining of formalin-fixed/paraffin-embedded tumor tissue samples, when available, was performed at a central laboratory (Department of Pathology, Tohoku University School of Medicine) \[[@CR24]\] using antibodies to ER (ER1D5; Immunotech, Marseille, France), PgR (MAB429; Chemicon International Inc., Temecula, California, USA), HER2 (AO485; DakoCytomation Co. Ltd., Kyoto, Japan), Ki67 (MIB-1; DakoCytomation), and epidermal growth factor receptor (EGFR) (Pharma Dx, DakoCytomation). HER2 status was determined using the Hercep Test, and samples with a score of 3+ were considered HER2-positive. Samples were considered EGFR-positive if they contained tumor cells with EGFR staining along the entire circumference of the cells. Lastly, Ki67 status was determined by calculating the percentage of Ki67-positive cells in a sample of at least 1,000 carcinoma cells, and was reported as Ki67 labeling index.

Hematologic and bone marker assessment {#Sec7}
--------------------------------------

Patient bone alkaline phosphatase and type I collagen cross-linked N telopeptide levels were assessed by chemiluminescent enzyme immunoassay and enzyme immunoassay, respectively. Patient high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol levels were assessed using enzymatic methods. All assays were performed by Mitsubishi BCL (currently, Mitsubishi Chemical Medience Corporation, Tokyo, Japan).

Statistical assessments {#Sec8}
-----------------------

This study was designed to confirm the TTP non-inferiority (80 % power) of exemestane versus anastrozole as initial hormone therapy in postmenopausal women with advanced breast cancer in. A hazard ratio (HR) of 0.9 for TTP in favor of exemestane was hypothesized based on previous clinical data and the target population of this study \[[@CR7], [@CR14], [@CR25], [@CR26]\]. Non-inferiority of exemestane versus anastrozole was prospectively defined as an upper bound of the 95 % confidence interval (CI) for the exemestane versus anastrozole HR no higher than 1.25 based on results of previous studies \[[@CR7], [@CR14], [@CR25], [@CR26]\]. To obtain 80 % power in this setting, 222 events (disease progression or breast cancer-related death) were required.

Efficacy was analyzed for all patients in the full analysis set (FAS) or in the per protocol set (PPS). The FAS included patients who were randomized, received at least 1 dose of study medication, and had at least 1 efficacy evaluation. The PPS included a subset of patients from the FAS who satisfied all inclusion criteria, did not meet any exclusion criteria, did not violate concomitant medication criteria, and had a total drug adherence rate of at least 80 %. The FAS was the primary efficacy analysis population.

The TTP HR and 95 % CI for exemestane versus anastrozole were calculated using a Cox proportional hazard model adjusting for key covariates (site of disease, postoperative adjuvant tamoxifen therapy, bisphosphonate use, and study site). Secondary TTP HRs with 95 % CI were determined using non-adjusted data (for FAS) or both adjusted and non-adjusted data (for PPS). Median TTP with 95 % CI was estimated for each treatment group by the Kaplan--Meier method.

For the FAS and PPS analysis populations, antitumor response point estimates and 95 % CI for each treatment group and the group difference were calculated and used to determine the rates of response and clinical benefit. Point estimates and 95 % CI were likewise calculated for intergroup differences in tumor responses. Median OS, median time to treatment failure, and 95 % CI were calculated by the Kaplan--Meier method. Investigator-assessed TTP was calculated in the same manner as the primary endpoint.

Safety data were summarized for all treated patients using descriptive statistics.

Results {#Sec9}
=======

Patient demographics and baseline characteristics {#Sec10}
-------------------------------------------------

Patients were enrolled between April 20, 2005, and December 17, 2010. Demographics and baseline characteristics were well balanced between treatment groups (Table [1](#Tab1){ref-type="table"}) \[[@CR24]\]. A total 298 patients were randomly assigned to receive treatment with exemestane (*n* = 149; mean age 63.4, range 44--95 years) or anastrozole (*n* = 149; mean age 64.0, range 45--94 years). The FAS population included 147 (98.7 %) and 145 (97.3 %) patients from the exemestane and anastrozole groups, respectively, whereas the PPS population included 142 (95.3 %) and 138 (92.6 %) patients from the exemestane and anastrozole groups, respectively (Fig. [1](#Fig1){ref-type="fig"}). Results of immunohistochemical detection of ER, PgR, HER2, androgen receptor, EGFR, and Ki67 (from 115 patients in the exemestane arm and 110 patients in the anastrozole arm) determined at a central laboratory are presented in Table [1](#Tab1){ref-type="table"}. The majority of patients with available histology data had tumors that stained positive for ER and/or PgR and negative for HER2. Table 1Patient demographics and baseline characteristicsExemestane (*n* = 149)Anastrozole (*n* = 149)Age, years Mean (SD)63.4 (9.3)64.0 (9.0) Range44--9545--94BMI, kg/m^2^ Mean (SD)23.0 (3.6)23.6 (4.5) Range15.4--39.115.0--38.2ECOG performance status, *n* (%) 0126 (84.6)118 (79.2) 123 (15.4)31 (20.8)Cause of menopause, *n* (%) Natural115 (77.2)125 (83.9) Medication14 (9.4)10 (6.7) Oophorectomy9 (6.0)3 (2.0) Hysterectomy9 (6.0)7 (4.7) Other2 (1.3)4 (2.7)Hematoxylin and eosin staining grade, *n* (%)(*n* = 113)(*n* = 107) I19 (16.8)18 (16.8) II56 (49.6)56 (52.3) III38 (33.6)33 (30.8)Estrogen receptor Allred score, *n* (%)(*n* = 115)(*n* = 110) ≥3109 (94.8)108 (98.2) \<36 (5.2)2 (1.8)Progesterone receptor Allred score, *n* (%)(*n* = 115)(*n* = 110) ≥392 (80.0)92 (83.6) \<323 (20.0)18 (16.4)HER2 score, *n* (%)(*n* = 115)(*n* = 110) 3+7 (6.1)7 (6.4) \<3+108 (93.9)103 (93.6)Androgen receptor staining intensity, *n* (%)(*n* = 114)(*n* = 110) ≥1 +107 (93.9)106 (96.4) 07 (6.1)4 (3.6)EGFR staining intensity, *n* (%)(*n* = 115)(*n* = 110) ≥110 (8.7)8 (7.3) 0105 (91.3)102 (92.7)KI67 labeling index, *n* (%)(*n* = 115)(*n* = 110) \>15 %49 (42.6)38 (34.5) ≤15 %66 (57.4)72 (65.5)Previous treatment, *n* (%) Radiotherapy35 (23.5)28 (18.8) Systemic therapy103 (69.1)100 (67.1)Stratification factors Sites of metastasis, *n* (%)  Visceral tissue75 (50.3)72 (48.3)  Bone only40 (26.8)40 (26.8)  Soft tissue only34 (22.8)37 (24.8)Patients receiving concomitant bisphosphonate therapy, *n* (%)37 (24.8)38 (25.5)Patients with no previous adjuvant tamoxifen or recurrence/metastasis for ≥1 year after surgery, *n* (%)124 (83.2)124 (83.2)Adapted with permission from Masuda et al. \[[@CR24]\]*BMI* body mass index, *ECOG* Eastern Cooperative Oncology Group, *EGFR* epidermal growth factor receptor, *HER2* human epidermal growth factor receptor 2, *SD* standard deviationFig. 1Study flowchart. *CT* computed tomography, *FAS* full analysis set, *MRI* magnetic resonance imaging, *PPS* per protocol set

Efficacy {#Sec11}
--------

Median TTP in the FAS population based on ERIRC assessment was 13.8 months (95 % CI: 10.8, 16.5 months) and 11.1 months (95 % CI: 10.8, 16.6 months) in the exemestane and anastrozole groups, respectively (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}a) \[[@CR24]\]. The adjusted HR for TTP in the exemestane versus anastrozole groups was 1.007 (95 % CI: 0.771, 1.317). Non-inferiority was not confirmed because the upper limit in the 95 % CI (1.317) was larger than the prespecified non-inferiority margin (1.25). Table 2Efficacy endpoint analysesEfficacy assessmentTreatment groupHazard ratio (95 % CI)*n*Exemestane*n*AnastrozoleERIRC-assessed TTP (FAS), months^a^ (95 % CI)14713.8 (10.8, 16.5)14511.1 (10.8, 16.6)1.007 (0.771, 1.317)Investigator-assessed TTP (FAS), months^a^ (95 % CI)14713.8 (10.0, 16.6)14513.7 (10.9, 16.6)1.059 (0.816, 1.374)ERIRC-assessed TTP (PPS), months^a^ (95 % CI)14213.8 (10.8, 16.5)13811.1 (9.2, 16.4)0.977 (0.746, 1.280)OS (FAS), months^a^ (95 % CI)147NR (49.1, NR)14560.1 (4.2, NR)1.062 (0.733, 1.539)TTF (FAS), months^a^ (95 % CI)14713.6 (9.2, 16.6)14511.1 (9.4, 14.1)1.078 (0.854, 1.362)Adapted with permission from Masuda et al. \[[@CR24]\]*CI* confidence interval, *ERIRC* expert radiologic images review committee, *FAS* full analysis set, *NR* not reached, *OS* overall survival, *PPS* per protocol set, *TTF* time to treatment failure, *TTP* time to progression^a^MedianFig. 2Kaplan--Meier plots of **a** time to progression (ERIRC-assessed) and **b** overall survival. *CI* confidence interval, *HR* hazard ratio, *NR* not reached, *OS* overall survival, *ERIRC* expert radiologic images review committee, *TTP* time to progression. Reproduced with permission from Masuda et al. \[[@CR24]\]

Additional secondary efficacy analyses demonstrated no significant differences between treatment groups. Although median OS was not reached in the exemestane group and was 60.1 months in the anastrozole group, the Kaplan--Meier plots indicated no difference in OS (Fig. [2](#Fig2){ref-type="fig"}b) \[[@CR24]\]. Median time to treatment failure in the FAS population was 13.6 months (95 % CI: 9.2, 16.6 months) and 11.1 months (95 % CI: 9.4, 14.1 months) in the exemestane and anastrozole groups, respectively. Tumor response was evaluable for 132 and 128 patients in the exemestane and anastrozole groups, respectively. Complete response was reported in approximately 2 % of patients in both the exemestane (*n* = 2) and anastrozole (*n* = 3) groups, and partial response was reported in 42.4 % (*n* = 56) and 36.7 % (*n* = 47) of patients in the exemestane and anastrozole groups, respectively (Table [3](#Tab3){ref-type="table"}) \[[@CR24]\]. Table 3Response ratesPatients, *n* (%)Exemestane (*n* = 132)Anastrozole (*n* = 128)Complete response2 (1.5)3 (2.3)Partial response56 (42.4)47 (36.7)Stable disease55 (41.7)70 (54.7) Stable disease ≥24 weeks41 (31.1)49 (38.3) Stable disease \<24 weeks14 (10.6)21 (16.4)Progressive disease16 (12.1)8 (6.3)Early death^a^1 (\<1.0)0Indeterminate response2 (1.5)0Overall response rate (CR + PR) \[95 % CI\]58 (43.9) \[35.3, 52.8\]50 (39.1) \[30.6, 48.1\]Clinical benefit response rate^b^ \[95 % CI\]99 (75.0) \[66.7, 82.1\]99 (77.3) \[69.1, 84.3\]Adapted with permission from Masuda et al. \[[@CR24]\]*CI* confidence interval, *CR* complete response, *PR* partial responseBased on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 \[[@CR23]\]^a^Cause of early death in 1 patient was lung metastasis^b^Clinical benefit response rate = (CR + PR + stable disease \> 24 weeks)/number of patients × 100

Safety {#Sec12}
------

AEs from any cause were reported in 136 patients (91.3 %) in the exemestane group and 131 patients (87.9 %) in the anastrozole group, whereas treatment-related AEs occurred in 106 patients (71.1 %) in the exemestane group and 89 patients (59.7 %) in the anastrozole group (Table [4](#Tab4){ref-type="table"}). Grade 3 or 4 AEs from any cause were reported in 28 patients (18.8 %) in the exemestane group and 27 patients (18.1 %) in the anastrozole group; grade 3 or 4 treatment-related AEs were reported in 13 patients (8.7 %) in the exemestane group and 9 patients (6.0 %) in the anastrozole group. The most common treatment-related AEs in either group were hot flush, arthralgia, and musculoskeletal stiffness (Table [5](#Tab5){ref-type="table"}) \[[@CR24]\]. Table 4Overall summary of adverse eventsExemestane (*n* = 149)Anastrozole (*n* = 149)Any causeTreatment-relatedAny causeTreatment-relatedTotal AEs, *n*687316796290Patients who experienced AEs, *n* (%) Any AE136 (91.3)106 (71.1)131 (87.9)89 (59.7) Serious AE19 (12.8)6 (4.0)19 (12.8)5 (3.4) Grade 3 or grade 4 AE^a^28 (18.8)13 (8.7)27 (18.1)9 (6.0) Grade 5 AE^b^3 (2.0)1 (0.7)1 (0.7)0Treatment discontinuation due to AE, *n* (%)10 (6.7)5 (3.4)9 (6.0)3 (2.0)*AE* adverse event^a^Based on Common Terminology Criteria for Adverse Events version 3.0 \[[@CR44]\]^b^Death related to AEs reported from start of treatment to 7 days after the end of treatment or study withdrawalTable 5Most common treatment-related adverse events occurring in ≥5 % of patientsTreatment-related adverse eventsPatients, *n* (%)Exemestane (*n* = 149)Anastrozole (*n* = 149)GradeGradeAny1--23--5Any1--23--5Hot flush33 (22)33 (22)022 (15)22 (15)0Arthralgia25 (17)24 (16)1 (1)25 (17)25 (17)0Musculoskeletal stiffness17 (11)17 (11)011 (7)11 (7)0GGT increased15 (10)11 (7)4 (3)5 (3)4 (3)1 (1)Hypoesthesia12 (8)12 (8)09 (6)9 (6)0Body weight increased11 (7)11 (7)05 (3)5 (3)0ALP increased9 (6)9 (6)05 (3)5 (3)0Decreased appetite9 (6)8 (5)1 (1)6 (4)6 (4)0Fatigue8 (5)8 (5)02 (1)2 (1)0Hypertension8 (5)7 (5)1 (1)10 (7)8 (5)2 (1)Reproduced with permission from Masuda et al. \[[@CR24]\]*ALP* alkaline phosphatase, *GGT* gamma-glutamyl transferaseBased on Common Terminology Criteria for Adverse Events version 3.0 \[[@CR44]\]

Serious AEs were reported in 19 patients (12.8 %) in each treatment group; serious AEs occurring in 2 or more patients were cataract and dyspnea (*n* = 2 each) in the exemestane group, and vomiting (*n* = 3), vertigo, pneumonia, and decreased appetite (*n* = 2 each) in the anastrozole group.

Overall, 10 patients (6.7 %) in the exemestane group and 9 patients (6.0 %) in the anastrozole group discontinued study treatment because of AEs. Abnormal hepatic function (*n* = 2 in the exemestane group) was the only AE leading to discontinuation in more than 1 patient. As shown in Fig. [1](#Fig1){ref-type="fig"}, 5 patients (2 from the exemestane group and 3 from the anastrozole group) did not have an efficacy assessment, but these patients were included in the safety analyses. None of these patients had a treatment-related serious AE.

There were 3 deaths in the exemestane group (acute myocardial infarction, metastases to lung, and breast cancer; *n* = 1 each) and 1 death in the anastrozole group (general physical health deterioration) as the result of AEs. Of these, only the acute myocardial infarction in the exemestane group was considered related to treatment.

No significant differences in laboratory test abnormalities were observed between treatment groups. Common grade 3 or higher laboratory test abnormalities (\>5 %) included gamma-glutamyl transferase (GGT) increase (9.4 %) and hyperglycemia (5.4 %) in the exemestane group and GGT increase (7.4 %), hypoalbuminemia (6.0 %), and hyperglycemia (5.4 %) in the anastrozole group (Table [6](#Tab6){ref-type="table"}). Table 6Common laboratory test abnormalitiesLaboratory parameterPatients, *n* (%)Exemestane (*n* = 149)Anastrozole (*n* = 149)Grade^a^Grade^a^34Any34AnyHemoglobin1 (0.7)028 (18.8)4 (2.7)039 (26.2)Lymphocytes (absolute)1 (0.7)1 (0.7)31 (20.8)3 (2.0)029 (49.5)Neutrophils (absolute)^b^1 (0.7)010 (6.8)2 (1.3)018 (12.1)WBCs (absolute)0014 (9.4)1 (0.7)017 (11.4)ALT0021 (14.1)0019 (12.8)ALP0065 (43.6)0068 (45.6)AST0025 (16.8)2 (1.3)028 (18.8)Creatinine0032 (21.5)1 (0.7)030 (20.1)GGT12 (8.1)2 (1.4)89 (60.1)9 (6.0)2 (1.3)73 (49.0)Hypercalcemia01 (0.7)20 (13.4)0011 (7.4)Hyperglycemia^b^8 (5.4)076 (51.4)8 (5.4)071 (47.7)Hyperkalemia1 (0.7)09 (6.0)1 (0.7)010 (10.1)Hypoalbuminemia0NA^c^16 (10.7)9 (6.0)NA^c^9 (6.0)*ALP* alkaline phosphatase, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *GGT* gamma-glutamyl transferase, *NA* not applicable, *WBC* white blood cell^a^Based on Common Terminology Criteria for Adverse Events version 3.0 \[[@CR44]\]^b^For this laboratory test, *n* = 148 in the exemestane group^c^Grade 4 hypoalbuminemia is not defined in CTCAE version 3.0

Bone markers increased slightly in both treatment groups throughout the observation period (Table [7](#Tab7){ref-type="table"}). No substantial change in total cholesterol, HDL-cholesterol, or LDL-cholesterol was observed in either treatment group; however, triglyceride was slightly decreased in the exemestane group. Table 7Bone and lipid markersBaselineMean % change from baseline (SD)Week 8Week 16Week 24End of studyExemestane Bone  *n*149131114107132  BAP, μg/L32.4 (19.4)11.1 (30.9)4.4 (35.9)6.9 (40.8)13.7 (46.6)  NTx, nmol^a^16.2 (7.7)4.63 (35.7)3.8 (37.5)8.4 (42.0)13.3 (47.2) Lipid  *n*149131114107144  TC, mg/dL207.5 (34.9)−2.0 (12.7)−1.6 (12.7)−1.4 (11.9)−1.9 (15.3)  HDL-C, mg/dL57.1 (14.0)−6.1 (15.5)−7.3 (13.9)−6.2 (13.7)−8.6 (15.0)  LDL-C, mg/dL127.9 (32.4)4.9 (20.0)5.9 (19.6)4.9 (18.6)3.5 (23.6)  TG, mg/dL135.3 (62.8)−12.3 (38.8)−8.4 (41.0)−13.3 (40.4)−11.5 (38.0)Anastrozole Bone  *n*149135121105142  BAP, μg/L35.3 (30.7)6.7 (28.2)2.8 (33.5)8.4 (41.2)12.8 (47.3)  NTx, nmol^a^17.6 (9.8)2.2 (33.8)5.4 (36.2)1.8 (37.2)12.6 (47.7) Lipid  *n*149135121105148  TC, mg/dL204.1 (35.3)4.1 (13.1)4.8 (13.7)5.9 (14.3)2.7 (15.1)  HDL-C, mg/dL58.5 (16.0)1.7 (14.4)3.7 (17.1)4.8 (15.0)1.5 (19.7)  LDL-C, mg/dL124.2 (32.5)5.8 (19.6)6.4 (18.7)7.9 (22.6)1.9 (22.1)  TG, mg/dL132.9 (67.5)1.9 (39.2)2.1 (46.8)−0.5 (40.4)2.2 (42.6)*BAP* bone alkaline phosphatase, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *NTx* type I collagen cross-linked N telopeptide, *SD* standard deviation, *TC* total cholesterol, *TG* triglyceride^a^Bone collagen equivalents/mmol creatinine

Discussion {#Sec13}
==========

In this study in postmenopausal women with advanced or recurrent breast cancer, TTP was similar with exemestane or anastrozole treatment (adjusted HR = 1.007; 95 % CI, 0.771, 1.317). However, the upper limit of the 95 % CI was above the prespecified non-inferiority margin of 1.25. No significant differences in investigator-assessed TTP, objective response rate, and clinical benefit rate between the exemestane and anastrozole treatment groups were observed in this study.

The results of this study are comparable to those reported in study NCIC CTG MA.27 comparing exemestane and anastrozole in the adjuvant setting for patients with early stage breast cancer, in which there was no statistically significant difference in event-free survival in the overall (HR = 1.02; *P* = 0.85), node-negative (HR = 1.04; *P* = 0.73), or node-positive (HR = 0.99; *P* = 0.90) populations \[[@CR19], [@CR20], [@CR27]\]. Likewise, median TTP in the exemestane (13.8 months) or anastrozole (11.1 months) groups in the current study was comparable to median TTP for exemestane in the overall (9.9 months) \[[@CR16]\] and Japanese (10.9 months) \[[@CR28]\] populations, respectively, in the EORTC 10951 phase 3 study in postmenopausal women with metastatic breast cancer, as well as historical TTP data reported for anastrozole and letrozole \[[@CR7], [@CR10], [@CR12], [@CR14], [@CR17]\]. Therefore, data from the current study are consistent with other reports demonstrating no differences in efficacy measures between AIs used as first-line treatment in patients with hormone-receptor-positive breast cancer.

The incidence of treatment-related AEs was higher in the exemestane group (71 %) versus the anastrozole group (60 %); however, most AEs were grade 1 or grade 2. The incidence of common AEs reported in this trial, including hot flush, arthralgia, and musculoskeletal stiffness, was consistent with previous comparisons of exemestane and anastrozole that found few differences between these agents in the adjuvant setting \[[@CR19], [@CR29]\].

Observed changes in plasma lipoproteins and bone markers were minimal between the two treatment groups in the current study. As reported in a recent systematic review, treatment with AIs did not correlate with any definitive change or unfavorable effect on plasma lipoproteins \[[@CR30]\], and in a sub-study of Japanese women from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial, exemestane or anastrozole treatment had no clinically significant effect on serum lipids in postmenopausal women with hormone-receptor-positive breast cancer \[[@CR31]\]. Musculoskeletal symptoms and decreased bone mineral density are anticipated effects of hormonal therapies, such as AIs, that produce menopause-like effects \[[@CR32]\]. In study MA.27, arthralgia, muscle pain, and fractures were reported in both the exemestane and anastrozole treatment groups; however, exemestane was associated with a significantly lower incidence of self-reported new-onset osteoporosis compared with anastrozole (*P* = 0.001) \[[@CR20], [@CR29]\]. Treatment algorithms for musculoskeletal AEs related to AI therapy have been developed, and discontinuation of AI therapy is rarely required \[[@CR33]--[@CR35]\].

In the present study, there was 1 death from acute myocardial infarction that was considered related to exemestane treatment, and no treatment-related deaths in the anastrozole group. Although results from two meta-analyses reported a higher risk of cardiovascular AEs associated with AIs compared with tamoxifen, these data have not been confirmed in a placebo-controlled trial, and available data do not support a substantial risk of ischemic cardiovascular events associated with AI treatment or differences in the risk of cardiovascular events for the different AIs \[[@CR29], [@CR30], [@CR36]--[@CR39]\]. Studies with longer follow-up time are needed to further define the cardiovascular safety profile of AI therapy.

Treatment guidelines have indicated no preference among approved AIs for patients with early breast cancer, and no efficacy or safety differences among AIs have been demonstrated in studies conducted in patients with advanced breast cancer \[[@CR20], [@CR40], [@CR41]\]. Additional studies may help identify prognostic factors or predictive markers to help provide optimized treatment for the individual patient. Several additional clinical trials directly comparing exemestane to other AIs in patients with advanced cancer are in progress and may yield additional information to aid in treatment decisions \[[@CR21], [@CR42], [@CR43]\].
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